Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial-Reference-Cited by-同舟云学术

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Published:2016-04 Issue:10030 Volume:387 Page:1837-1846
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Fehrenbacher Louis,Spira Alexander,Ballinger Marcus,Kowanetz Marcin,Vansteenkiste Johan,Mazieres Julien,Park Keunchil,Smith David,Artal-Cortes Angel,Lewanski Conrad,Braiteh Fadi,Waterkamp Daniel,He Pei,Zou Wei,Chen Daniel S,Yi Jing,Sandler Alan,Rittmeyer Achim

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line;Al-Farsi;Front Oncol,2014

2. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat Rev Immunol,2008

3. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

5. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

Cited by 2281 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?;Mathematical Biosciences;2024-10

2. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

3. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

4. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09

5. Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma;Cancer Medicine;2024-09